BioSpace News Archive

Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company (“Deerfield”), a healthcare investment firm, today announced a new study that shows incorporating genetic evidence into drug design significantly increases the probability of successful development by up to 2.6 times compared to when genetic evidence is absent.

RaySearch Laboratories AB is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®.

BAP Pharma will welcome guests and dignitaries to the Grand Opening Ceremony of its new headquarters on Randolph Road with a formal ribbon cutting ceremony, speeches, and exclusive tours of the new facility.

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that...

Culture Biosciences is proud to announce the appointment of Darcy Birse as its new Chief Executive Officer.

Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection significantly reduced the apnea-hypopnea index compared to placebo, achieving the primary endpoints.

Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer and Samarendra Mohanty, PhD, President and Chief Scientific Officer will present and participate in a panel discussion at the World Orphan Drug Congress 2024, taking place from April 23-25, 2024 in Boston, Massachusetts.

Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.

Bionano Genomics, Inc. (BNGO), a global leader in the transformation of the cytogenetic workflow with OGM, today announced that it has entered into an original equipment manufacturing (OEM) partnership agreement with Diagens, an assisted reproductive technology company based in China focused on the application of AI in cytogenetics.

Halia Therapeutics today announced that David J. Bearss , Ph.D., President and CEO of Halia Therapeutics, will present at the Asia BIO 2024 Conference on April 24.